AbbVie
ABBV
$168.16
Share price
-0.82%
Change (1 day)
2.48%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Market capitalization of AbbVie (ABBV)
Market cap: $297.74 Billion
As of April 2024 AbbVie has a market cap of $297.74 Billion. This makes AbbVie the world's 33th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of AbbVie from 2012 to 2024
End of year Market Cap
| Year | Market cap | Change |
|---|---|---|
| 2024 | $297.74 B | 8.82% |
| 2023 | $273.60 B | -4.27% |
| 2022 | $285.80 B | 19.4% |
| 2021 | $239.37 B | 26.54% |
| 2020 | $189.17 B | 44.47% |
| 2019 | $130.94 B | -3.95% |
| 2018 | $136.33 B | -11.7% |
| 2017 | $154.39 B | 51.71% |
| 2016 | $101.76 B | 6.7% |
| 2015 | $95.37 B | -8.42% |
| 2014 | $104.14 B | 24.23% |
| 2013 | $83.82 B | 55.32% |
| 2012 | $53.97 B |
End of Day market cap according to different sources
On Apr 23rd, 2024 the market cap of AbbVie was reported to be:
$300.19 Billion
$300.19 Billion
$300.19 Billion
$299.45 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $148.10 B | -50.26% | 🇺🇸 USA |
 Eli Lilly LLY | $698.97 B | 134.76% | 🇺🇸 USA |
 Amgen AMGN | $146.63 B | -50.75% | 🇺🇸 USA |
 Biogen BIIB | $29.52 B | -90.08% | 🇺🇸 USA |
 Gilead Sciences GILD | $83.09 B | -72.09% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $98.86 B | -66.80% | 🇺🇸 USA |
 AstraZeneca AZN | $219.77 B | -26.19% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $83.41 B | -71.98% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $14.13 B | -95.25% | 🇺🇸 USA |